Mind + Muscle

technical minds + legal muscle


dig deep

New U.S. Law Establishes Long Awaited Abbreviated Approval Pathway for Biosimilars

  • 04.12.10
  • Timothy J. Shea, Jr. and Tracy L. Muller

On March 21, 2010, the U.S. Congress passed landmark healthcare reform legislation, known as the "Patient Protection and Affordable Care Act," that will dramatically reshape the biopharmaceutical industry. This historic piece of legislation contains provisions that establish, for the first time ever, an abbreviated regulatory approval pathway for generic versions of biological medicines (i.e., biosimilars) in the United States. Click here to read the full article.

Related People

Related Industries

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.